Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story
Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures, expanding its urologic stone management portfolio in the United States. This launch tests the company's execution capabilities amidst a mixed stock performance, a microbiology pouch recall, and new leadership in BD Interventional. Investors will be watching the adoption rate of the Elyra system and the company's ability to maintain product reliability and address its debt levels.
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BD (Becton, Dickinson and Company) has launched the Elyra Thulium Fiber Laser (TFL) System, an advanced medical device designed to improve efficiency and versatility in kidney stone management and soft tissue procedures. This new system, available in two configurations, uses advanced TFL technology to streamline kidney stone treatment and boasts an intuitive user interface and rapid startup. Despite the innovation, BD's stock saw a slight dip, but the company anticipates long-term growth by strengthening its urologic stone management portfolio in a growing market.
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
Becton, Dickinson and Company (BD) has launched the Elyra Thulium Fiber Laser (TFL) System, an advanced platform for kidney stone management and soft tissue procedures, aiming to enhance efficiency and versatility in urologic care. Despite a recent dip in stock price, this innovation is expected to strengthen investor confidence and BD's competitive position in the growing urology market. The system features advanced TFL technology for efficient stone dusting, a compact design, and user-friendly features, with early clinical procedures already yielding positive feedback.
How syringe-maker BD is using AI to stay sharp
Becton Dickinson (BD), a leading medical device company, is integrating AI and automation with "lean manufacturing" principles to boost efficiency and innovation. CEO Tom Polen has implemented the BD Excellence program, which combines Toyota's continuous improvement methods with AI vision systems and robotics to optimize production and reduce waste. The strategy aims to empower employees, enhance productivity, and reposition BD for future growth beyond traditional medical devices into areas like AI sensors and regenerative medicine.
Robotic surgery gets telepresence, force-sensing tools in Intuitive upgrade
Intuitive (Nasdaq: ISRG) announced significant innovations for its da Vinci 5 robotic surgical system, including enhanced telepresence capabilities, expanded uses for Force Feedback instruments, and improved product reliability and security. These updates aim to advance patient care, optimize surgeon experience, and reduce costs, with features like a full-OR telepresence camera, mobile console login, new training modules, and an anticipated increase in instrument uses by 2027. The company also highlighted strong da Vinci 5 adoption, with over 1,400 systems installed globally and 380,000 procedures performed, along with a guaranteed 98% uptime exceeding 99% actual performance.
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
BD (Becton, Dickinson and Company) has launched the Elyra™ Thulium Fiber Laser (TFL) System, designed to enhance kidney stone care for urology teams. This advanced laser platform aims to improve efficiency, versatility, and workflow in urologic stone management and soft tissue procedures. The system features Thulium Fiber Laser technology for efficient stone dusting and reduced migration, along with an air-cooled design for quieter operation and a smaller footprint.
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
BD (Becton, Dickinson and Company) has launched the Elyra™ Thulium Fiber Laser (TFL) System, designed to enhance kidney stone care for urology teams. This advanced laser platform offers improved efficiency, versatility, and workflow for stone management and soft tissue procedures, featuring quiet operation and a smaller footprint. The system, available in Elyra™ and Elyra™ Plus configurations, has received positive feedback from initial clinical cases and expands BD's comprehensive portfolio for urologic stone management.
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) recently reported a Q2 net loss despite solid sales, while affirming full-year revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. Investors are watching how the company navigates short-term profitability pressures, a microbiology pouch recall, and aims to drive long-term growth through product innovation and strategic partnerships like the expanded agreement with Bactiguard. The new leadership and focus on infection prevention are key to reshaping BD's investment narrative amidst quality scrutiny.
May 20, 2026 - 8-A12B: Registration of securities [Section 12(b)]
Becton, Dickinson and Company (BDX) and Becton Dickinson Euro Finance S.à r.l. have filed a Form 8-A12B registration statement for securities with the SEC. This filing relates to the registration of €600,000,000 aggregate principal amount of 3.855% Notes due 2033, issued by Becton Finance and guaranteed by BD, which will be registered on the New York Stock Exchange. The document incorporates by reference details from previous filings concerning the Notes' description and related indentures.
Becton Dickinson subsidiary issues €600 million in 3.855% notes due 2033
Becton Dickinson Euro Finance S.à r.l., a subsidiary of Becton, Dickinson and Company (NYSE:BDX), has completed an offering of €600 million in 3.855% notes due 2033. The company plans to use the proceeds, along with cash on hand, to repay existing 1.208% notes due in June 2026 and for general corporate purposes. This issuance adds to Becton Dickinson's total debt, though it maintains a "GOOD" financial health rating and a manageable debt-to-equity ratio.
BECTON, DICKINSON AND COMPANY
This 8-K current report from Becton, Dickinson and Company details the issuance of €600,000,000 aggregate principal amount of 3.855% Notes due 2033 by its indirect, wholly-owned subsidiary, Becton Dickinson Euro Finance S.à r.l. These "Becton Finance Notes" are fully and unconditionally guaranteed by BD and are intended to repay existing notes and for general corporate purposes. The filing outlines the terms, conditions, and redemption options for these notes.
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.
Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt
Becton Dickinson, through its subsidiary Becton Dickinson Euro Finance, has issued €600 million of 3.855% senior unsecured notes due in 2033. The company plans to use the proceeds, along with existing cash, to repay its 1.208% notes maturing in June 2026 and for general corporate purposes. The agreement details specify a 7-year duration for the notes, maturing on May 20, 2033.
Barclays (DJP) sells $2.63M AutoCallable Contingent Coupon Notes, 9.70% p.a.
Barclays Bank PLC is offering $2.63 million in AutoCallable Contingent Coupon Notes, set to mature on May 23, 2029, with a contingent annual coupon rate of 9.70%. These notes are linked to the performance of four equity securities: BDX, GEHC, ZBH, and DHR, and investors' principal repayment at maturity is subject to the performance of the least performing reference asset. The offering includes potential risks such as loss of principal, dependence on Barclays' creditworthiness and the U.K. Bail-in Power, and limited upside potential compared to direct equity ownership.
Shareholders Will Be Pleased With The Quality of Becton Dickinson's (NYSE:BDX) Earnings
Becton Dickinson's recent earnings report, despite a subdued stock price reaction, indicates underlying strength. The company's profits were reduced by US$1.3 billion due to unusual items, which are generally non-recurring, suggesting potential for increased profit in the future if these expenses subside. Becton Dickinson has also shown consistent earnings per share growth of 5.7% annually over the last three years.
IDEXX Laboratories (Nasdaq:IDXX) - Stock Analysis
This report provides a comprehensive stock analysis of IDEXX Laboratories (IDXX), covering its market performance, financial health, future growth predictions, and recent news. Key highlights include its Q1 2026 revenue growth and increased full-year guidance, driven by strong diagnostics and new product integration like the SDMA kidney biomarker. The analysis also touches on analyst sentiment, insider transactions, and comparisons to competitors.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production, expanding cell and gene therapy pipelines, and increasing adoption of serum-free formulations. Key players like Avantor, Thermo Fisher Scientific, and Lonza Group AG are focusing on scalable GMP production and advanced media platforms to meet demand. The serum-free media segment and cancer research application are expected to lead market growth, with China, Japan, and Germany showing the fastest regional expansion.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, at a CAGR of 6.6%. This growth is driven by the increasing demand for biologics, cell and gene therapies, and the shift towards serum-free formulations, with key players including Avantor, Thermo Fisher Scientific, and Lonza Group AG. The market focuses on scalable, GMP-grade manufacturing inputs, with significant growth expected in Asia-Pacific markets like China and Japan, as well as European countries and the US.
Avantor hands global quality and regulatory oversight to new EVP Jerry Porreca
Avantor (NYSE: AVTR) has appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective May 19, 2026. In this role, he will oversee global quality assurance, quality systems, and regulatory affairs across all Avantor businesses. Porreca brings extensive experience from previous senior roles at Getinge, Becton Dickinson, C.R. Bard, and Smith+Nephew, which Avantor expects will be crucial for scaling operations and maintaining high standards for its life sciences and advanced technology customers.
Avantor Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor, Inc. has announced the appointment of Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca will oversee global quality assurance, quality systems, and regulatory affairs for all Avantor's businesses. He brings extensive experience from previous leadership positions at Getinge, Becton Dickinson and Company, C.R. Bard, Inc., and Smith+Nephew plc, enhancing Avantor's commitment to high standards in the life sciences and advanced technology sectors.
Becton, Dickinson and Company Appoints Peter Menziuso as Executive Vice President and President, Bd Interventional, Effective June 1, 2026
Becton, Dickinson and Company announced the appointment of Peter Menziuso as Executive Vice President and President, BD Interventional, effective June 1, 2026. Menziuso brings over 30 years of global healthcare leadership experience, having previously served as Company Group Chairman of Johnson & Johnson Vision. His proven track record in driving growth, building high-performing teams, and operational excellence is expected to accelerate BD Interventional's execution and growth.
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call
BioCardia discussed positive results for its CardiAMP Cell Therapy for ischemic heart failure during its Q1 2026 conference call. Blinded echocardiography data from the CardiAMP Heart Failure trial, analyzed by Yale University, showed treated patients maintained stable heart volumes, unlike control subjects. The therapy, which has FDA breakthrough designation and Medicare reimbursement, showed statistically significant benefits in a subgroup with elevated heart stress biomarkers, aligning with a composite endpoint for improved long-term outcomes.
Baxter Board Size Reset Puts Governance Changes In Focus For Investors
Baxter International (NYSE:BAX) recently received shareholder approval to amend its certificate of incorporation and bylaws, adjusting the framework for its board size to between seven and twelve directors. This governance change is viewed as a tool to reshape oversight and potentially bring in fresh expertise, especially in light of the company's weak share performance over the past five years. Investors are now watching for future announcements regarding new director appointments, committee reshuffles, or changes in capital allocation policies to assess how this flexibility will be utilized to address operational and financial challenges.
Becton Dickinson stock (US0718131099): leadership change and steady medtech demand in focus
Becton Dickinson (BDX) has appointed Peter Menziuso as the new executive vice president and president of its Interventional segment, a move closely watched by investors. The company's business model relies on supplying high-volume medical devices and diagnostics, with revenue drivers including syringes, needles, diagnostic platforms, and interventional products. BDX shares are currently trading in the mid-range of their 52-week corridor on the NYSE, with performance influenced by healthcare spending, interest rates, and the company's ability to execute on manufacturing and quality amidst regulatory and pricing pressures.
BD Interventional Appoints Peter Menziuso EVP and President
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026. Menziuso brings over 30 years of global healthcare leadership experience, most recently serving as company group chairman of Johnson & Johnson Vision. He is expected to leverage his experience to accelerate execution and drive continued growth for BD Interventional.
Peter Menziuso Named EVP and President, BD Interventional
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as Executive Vice President and President, BD Interventional, effective June 1. Menziuso brings over 30 years of global healthcare leadership experience, having previously served as Company Group Chairman of Johnson & Johnson Vision. His proven track record in driving growth and operational excellence is expected to further accelerate BD Interventional's performance.
Embecta closes Owen Mumford acquisition for up to $201M
Embecta has finalized its acquisition of Owen Mumford Holdings for an upfront payment of 100 million pounds plus up to 50 million pounds in performance-based payments, totaling potentially $201 million. This acquisition helps Embecta, traditionally focused on diabetes care, expand into broader medical supplies and markets such as autoimmune diseases and anaphylaxis, leveraging Owen Mumford's auto-injector platform and manufacturing capabilities. The deal is expected to contribute to Embecta's revenue growth starting in its 2027 fiscal year.
BD taps former J&J leader as new president of Interventional
BD has appointed Peter Menziuso, a former Johnson & Johnson Vision leader, as the new EVP and president of its Interventional segment, effective June 1. Menziuso will succeed Rick Byrd, who announced his retirement last month. With over 30 years in the healthcare industry, Menziuso is expected to drive continued growth for BD Interventional, which focuses on surgical, endovascular, urological, and critical care solutions.
BD Names Peter Menziuso to Lead $BD Interventional Business
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1. Menziuso, formerly of Johnson & Johnson Vision, brings extensive experience in commercial operations, R&D, manufacturing, and supply chain management. His appointment aims to steer BD's Interventional segment towards continued growth, focusing on operational efficiency and market expansion in the evolving medical device sector.
Peter Menziuso Named EVP and President, BD Interventional
BD (Becton, Dickinson and Company) announced Peter Menziuso as the new executive vice president and president of BD Interventional, effective June 1. Menziuso brings over 30 years of global healthcare leadership, most recently from Johnson & Johnson Vision. He is recognized for his strong track record in driving growth, market leadership, and building high-performing teams, which BD anticipates will accelerate execution and sustained growth for its Interventional segment.
Peter Menziuso Named EVP and President, BD Interventional
BD (Becton, Dickinson and Company) has announced the appointment of Peter Menziuso as executive vice president and president of BD Interventional, effective June 1. Menziuso brings over 30 years of global healthcare leadership experience, most recently serving as Company Group Chairman of Johnson & Johnson Vision, where he managed a $5 billion global business. His appointment is expected to drive continued growth and reinforce leadership within BD Interventional.
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock?
Becton, Dickinson and Company (BDX) has underperformed the broader market and its sector, despite spinning off its Biosciences & Diagnostic Solutions business to become a pure-play MedTech company. While the company reported better-than-expected Q2 results and raised its FY26 adjusted EPS projection slightly, the forecast is still below pre-spinoff expectations. Wall Street analysts maintain a "Moderate Buy" consensus, with Barclays recently raising its price target, indicating potential upside for the stock.
Becton Dickinson stock (US0718131099): steady diagnostics demand meets new earnings impulse
Becton Dickinson (BDX) has released new quarterly figures and an updated outlook, highlighting solid core growth in medical and life sciences despite the fading impact of pandemic-related testing revenue. As a key healthcare supplier, the company's performance is driven by recurring demand for consumables, capital equipment sales, and continuous product innovation in areas like drug delivery and lab automation, particularly benefiting from its strong presence in US hospitals and labs.
Becton Dickinson and Co stock (US0758871091): earnings beat and strategic focus keep medtech giant in the spotlight
Becton Dickinson and Co (BDX) reported stronger-than-expected Q2 2026 earnings, with adjusted EPS of $2.90 against a consensus of $2.77, and revenue of $4.71 billion. The medical technology giant continues to reshape its portfolio and focuses on developing medical devices, diagnostic systems, and interventional products. The article highlights its core business model, recent financial performance, dividend growth, and competitive positioning within the evolving healthcare industry.
Q1 Earnings Highs And Lows: STERIS (NYSE:STE) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks
This article analyzes the Q1 2026 earnings performance of STERIS (NYSE:STE) and its peers in the surgical equipment & consumables - diversified industry. While STERIS's revenue was in line with expectations, it showed the weakest performance against estimates among its peers. The report also highlights the strong performance of Zimmer Biomet (NYSE:ZBH), BD (NYSE:BDX), Solventum (NYSE:SOLV), and CONMED (NYSE:CNMD), noting their revenue figures and market reactions.
User | poteaudailynews.com - Embecta Corp. - Common Stock (Nasdaq:EMBC) Stock Quote
This article provides a stock quote and related news for Embecta Corp. (NASDAQ: EMBC). It details the current stock price, trading volume, bid/ask prices, range, dividend yield, and recent performance, showing a significant year-to-date decline. Additionally, it lists recent news headlines concerning Embecta's quarterly reports, business strategies, and stock performance.
Axogen (AXGN) Valuation Check After Strong Recent Share Price Momentum
Axogen (AXGN) has seen strong recent share price momentum, with a 3-year return over 3x, and is considered 19.3% undervalued by its most followed narrative, suggesting a fair value of $50.78 per share due to anticipated FDA approval for Avance Nerve Graft and resultant market exclusivity. However, its current P/S ratio of 9.2x is significantly higher than the industry average, indicating a premium valuation and potential risk if growth or regulatory progress falters. Investors are encouraged to assess the balance of risk and reward by looking at the company's financials for themselves.
Baxter International stock (US0718131099): Q1 update highlights mixed sales and margin pressure
Baxter International reported mixed Q1 results with softer sales in some units and continued margin pressure, impacting investor focus on the medtech company. The company's performance is tied to healthcare utilization, procurement cycles, and reimbursement conditions, making execution and margin recovery central to its outlook. Investors are watching for signs that revenue growth translates into operating leverage, particularly given Baxter's significant presence in the U.S. healthcare system through its renal care, hospital products, and infusion systems.
Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target
Becton Dickinson (BDX) reported solid fiscal Q2 performance, with revenue increasing 2.6% to $4.7 billion, driven by strong growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. Barclays reiterated an Overweight rating and raised its price target for BDX to $204 from $202, citing the company's operational growth exceeding expectations and its strong market position. The company also gained market share in its Alaris business and secured significant long-term customer agreements in the BioPharma Systems segment, despite minor setbacks from product ship holds due to an FDA warning letter.
West Pharmaceutical Cyberattack Tests Operational Resilience And Investor Risk Assumptions
West Pharmaceutical Services (NYSE:WST) experienced a material cybersecurity incident involving data exfiltration and system encryption, leading to a temporary suspension of global operations. This event prompts investors to consider not just temporary downtime, but also potential regulatory scrutiny, data privacy obligations, and legal claims, challenging the company's operational resilience narrative. The article advises focusing on the speed of operational restoration, disclosures about accessed data, and the cost of remediation to assess the long-term impact on WST's stock.
Becton Dickinson stock (US0718131099): earnings update and outlook for the medical technology group
Becton Dickinson reported its second-quarter fiscal 2024 results, showing revenue and adjusted earnings growth and reconfirming its full-year outlook. The medical technology group highlighted growth drivers in diagnostics and diabetes care, emphasizing its role in syringes, infusion therapy, and diagnostic systems. Despite facing industry challenges like regulatory complexity and price pressure, the company remains a key player for US investors looking for exposure to long-term healthcare trends.
SmartPort Surgery Lawsuit Claims AngioDynamics Catheter Fractured Inside Woman’s Body
A Missouri woman has filed a product liability lawsuit against AngioDynamics Inc. and Navilyst Medical Inc., alleging that an AngioDynamics SmartPort catheter fractured inside her body, requiring surgical removal of a broken segment from major veins near her heart. The lawsuit claims the SmartPort was defectively designed and manufactured, and that the company concealed a higher failure rate compared to similar devices. This case joins numerous other AngioDynamics lawsuits consolidated in a multidistrict litigation, raising similar allegations against the manufacturers for alleged negligence, design defects, and failure to warn.
Becton Dickinson stock (US0718131099): Antitrust case survives dismissal
A Pennsylvania federal court has denied the dismissal of an antitrust lawsuit against Becton Dickinson, brought forth by Tela Bio Inc. The case, which revolves around allegations concerning hernia mesh products, will now proceed, adding legal pressure on the medical device company. Despite this, Becton Dickinson's core operations in medical devices are considered robust, with analysts projecting revenue and earnings growth.
Jim Cramer Makes Big Claim About Beckton Dickinson (BDX)
Jim Cramer commented on Becton, Dickinson and Company (NYSE:BDX), noting its historically low stock price despite being a healthcare company. While analyst ratings have been reduced, Cramer insists on sticking with the stock, acknowledging that healthcare stocks are currently struggling. The article also suggests that AI stocks might offer greater and faster returns than BDX.
Becton Dickinson (BIT:1BDX) - Stock Analysis
Becton Dickinson (BIT:1BDX) is trading below its estimated fair value with earnings forecast to grow by 9.63% per year, and pays a reliable dividend of 2.91%. The company recently appointed a new CFO, declared a quarterly dividend, and launched several innovative medical products including the BD CentroVena One Insertion System and the BD PureWick Urine Collection System. Becton Dickinson continues to expand its portfolio with advancements in portal hypertension care, AI-powered immunology research tools, breast biopsy systems, and connected care platforms.
Becton Dickinson stock (US0718131099): Medical technology leader with global reach
Becton Dickinson (BD), a global medical technology company, is a key player in medical devices and diagnostics, providing products like syringes and diagnostic systems. The company's business model is built around three segments: BD Medical, BD Life Sciences, and BD Interventional, generating steady revenue primarily from consumables. BD offers US investors exposure to defensive healthcare growth, with a strong dividend history and market leadership, though potential investors should consider regulatory risks and high debt from past mergers.
Is Waters Corporation (WAT) A Good Stock To Buy Now?
This article summarizes a bullish thesis on Waters Corporation (WAT), highlighting its recent share price selloff after its Q4 2025 results and a transformative merger with BD’s Biosciences and Diagnostic Solutions division, which presents an attractive entry point. The company boasts strong fundamentals, recurring revenue from consumables and services, and consistent profitability, with the merger expected to drive significant growth and synergies. Despite short-term integration risks, Waters' discounted valuation and robust cash flows position it for potential multiple expansion and sustained shareholder returns.
Becton Dickinson stock (US0718131099): Medical technology leader with steady US market presence
Becton Dickinson (BD) maintains a strong position in the US medical technology sector, offering solutions for diagnostics, medical devices, and pharmaceutical systems. The company operates through BD Medical, BD Life Sciences, and BD Interventional, serving critical healthcare needs with products like infusion pumps, diagnostic tools, and devices for surgical interventions. BD's focus on safety, innovation, and compliance, coupled with its NYSE listing and primary revenue from North America, makes it an attractive investment in the resilient US healthcare economy.
Becton Dickinson Announces €600 Million Senior Notes Offering
Becton Dickinson and its Luxembourg-based financing subsidiary have announced a €600 million offering of 3.855% notes due 2033. The proceeds, along with cash on hand, will be used to repay existing euro notes due in June 2026, aiming to extend debt maturities and enhance financial flexibility. While an analyst rates BDX as a Buy with a $204.00 price target, TipRanks' AI Analyst, Spark, notes a "Neutral" outlook due to strong cash flow and improved leverage balanced against recent revenue softness and a technically weak chart.
[10-Q] WATERS CORP /DE/ Quarterly Earnings Report
Waters Corporation (WAT) filed its quarterly earnings report (Form 10-Q) for the period ended April 4, 2026. This report highlights the significant impact of the Biosciences & Diagnostic Solutions (BDS) Business Acquisition, which closed on February 9, 2026, on the company's financial results. While total revenue increased by 91% to $1.267 billion, operating income declined significantly to a loss of $47 million due to acquisition-related expenses, including fair value step-up expenses and increased intangibles amortization.
